These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1108 related articles for article (PubMed ID: 18384820)
1. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits. Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820 [TBL] [Abstract][Full Text] [Related]
2. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Wang HY; Friedman E; Olmstead MC; Burns LH Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657 [TBL] [Abstract][Full Text] [Related]
3. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells. Clark MJ; Traynor JR J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633 [TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with the opioid antagonist naltrexone favours the coupling of spinal cord μ-opioid receptors to Gαz protein subunits. Valdizán EM; Díaz A; Pilar-Cuéllar F; Lantero A; Mostany R; Villar AV; Laorden ML; Hurlé MA Neuropharmacology; 2012 Feb; 62(2):757-64. PubMed ID: 21903117 [TBL] [Abstract][Full Text] [Related]
5. Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization. Clark MJ; Neubig RR; Traynor JR J Pharmacol Exp Ther; 2004 Jul; 310(1):215-22. PubMed ID: 15014136 [TBL] [Abstract][Full Text] [Related]
6. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein. Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558 [TBL] [Abstract][Full Text] [Related]
7. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. Murthy KS; Makhlouf GM Mol Pharmacol; 1996 Oct; 50(4):870-7. PubMed ID: 8863832 [TBL] [Abstract][Full Text] [Related]
8. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor. Xu H; Wang X; Wang J; Rothman RB Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220 [TBL] [Abstract][Full Text] [Related]
9. G(z) can mediate the acute actions of mu- and kappa-opioids but is not involved in opioid-induced adenylyl cyclase supersensitization. Tso PH; Wong YH J Pharmacol Exp Ther; 2000 Oct; 295(1):168-76. PubMed ID: 10991975 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. Clark MJ; Furman CA; Gilson TD; Traynor JR J Pharmacol Exp Ther; 2006 May; 317(2):858-64. PubMed ID: 16436499 [TBL] [Abstract][Full Text] [Related]
11. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells. Zhang L; Tetrault J; Wang W; Loh HH; Law PY Mol Pharmacol; 2006 Jun; 69(6):1810-9. PubMed ID: 16525132 [TBL] [Abstract][Full Text] [Related]
12. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494 [TBL] [Abstract][Full Text] [Related]
13. Mu-opioid receptor regulation during opioid tolerance and supersensitivity in rat central nervous system. Diaz A; Ruiz F; Flórez J; Hurlé MA; Pazos A J Pharmacol Exp Ther; 1995 Sep; 274(3):1545-51. PubMed ID: 7562532 [TBL] [Abstract][Full Text] [Related]
14. mu-Opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance dopamine-stimulated activity of type VII adenylyl cyclase. Yoshimura M; Ikeda H; Tabakoff B Mol Pharmacol; 1996 Jul; 50(1):43-51. PubMed ID: 8700117 [TBL] [Abstract][Full Text] [Related]
15. Inhibitory GTP-binding regulatory protein Gi3 can couple angiotensin II receptors to inhibition of adenylyl cyclase in hepatocytes. Pobiner BF; Northup JK; Bauer PH; Fraser ED; Garrison JC Mol Pharmacol; 1991 Aug; 40(2):156-67. PubMed ID: 1908548 [TBL] [Abstract][Full Text] [Related]
16. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Traynor JR; Nahorski SR Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747 [TBL] [Abstract][Full Text] [Related]
17. Regulation of dihydropyridine-sensitive Ca++ channels during opioid tolerance and supersensitivity in rats. Díaz A; Ruíz F; Flórez J; Pazos A; Hurlé MA J Pharmacol Exp Ther; 1995 Sep; 274(3):1538-44. PubMed ID: 7562531 [TBL] [Abstract][Full Text] [Related]
18. Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. Wang HY; Burns LH J Neurobiol; 2006 Oct; 66(12):1302-10. PubMed ID: 16967511 [TBL] [Abstract][Full Text] [Related]
19. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling. Szücs M; Boda K; Gintzler AR J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951 [TBL] [Abstract][Full Text] [Related]
20. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors. Puttfarcken PS; Werling LL; Cox BM Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]